Form 8-K - Current report:
SEC Accession No. 0001104659-24-093448
Filing Date
2024-08-27
Accepted
2024-08-27 16:30:18
Documents
16
Period of Report
2024-08-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2422347d1_8k.htm   iXBRL 8-K 50789
2 EXHIBIT 10.1 tm2422347d1_ex10-1.htm EX-10.1 1114419
3 EXHIBIT 99.1 tm2422347d1_ex99-1.htm EX-99.1 15127
7 GRAPHIC tm2422347d1_annex1img001.jpg GRAPHIC 10299
  Complete submission text file 0001104659-24-093448.txt   1622254

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA egrx-20240821.xsd EX-101.SCH 3012
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE egrx-20240821_lab.xml EX-101.LAB 34240
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE egrx-20240821_pre.xml EX-101.PRE 22357
18 EXTRACTED XBRL INSTANCE DOCUMENT tm2422347d1_8k_htm.xml XML 3701
Mailing Address 50 TICE BOULEVARD, SUITE 315 WOODCLIFF LAKE NJ 07677
Business Address 50 TICE BOULEVARD, SUITE 315 WOODCLIFF LAKE NJ 07677 201-326-5300
EAGLE PHARMACEUTICALS, INC. (Filer) CIK: 0000827871 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36306 | Film No.: 241249456
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)